Atom Therapeutics Co

What Atom Therapeutics Co does

Atom Therapeutics Co., Ltd is a privately held, clinical-stage biotechnology company founded in March 2012 by Dr. William (Dongfang) Shi as Atom Bioscience, subsequently rebranded in November 2024. Headquartered in Hangzhou, China, with additional offices in Suzhou, China and Newark, California (Atom Therapeutics America, Inc.), the company employs 11–50 staff and has raised approximately $170 million USD across multiple venture rounds, including an $83 million Series D led by Kaitai Capital in October 2023.

The company's core pipeline consists of small-molecule therapeutics for inflammatory, metabolic, and cardiovascular diseases. Its lead asset is ABP-671 (lingdolinurad), a patented URAT1 inhibitor designed as a once-daily oral tablet for chronic gout and hyperuricemia, currently in global Phase 3 trials synchronized between the US and China (with the first Chinese Phase 3 patient dosed in June 2026). ABP-745 is a novel anti-inflammatory small molecule in Phase 2 development for both acute gout flares and, as of FDA approval in December 2025, atherosclerotic cardiovascular disease (ASCVD). Earlier-stage candidates include ABP-6118, a xanthine oxidase inhibitor for gout, and ABP-431, an anticancer compound.

Atom Therapeutics is pre-revenue and operates a licensing-driven commercial model. In December 2024, it granted China Medical System Holdings Ltd (CMS) exclusive commercialization rights to lingdolinurad in mainland China, Hong Kong, and Macao, while retaining development and commercialization rights for other global markets. Forward commercialization in those retained geographies is planned through direct sales or additional partnerships, supported by business-development outreach at major industry events such as BIO-Europe 2025.

Name

Atom Therapeutics Co

Legal name

Atom Therapeutics Co., Ltd

Website

https://atomthera.us

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Atom Therapeutics is a clinical-stage Chinese-American biotechnology company developing patented small-molecule drugs — led by URAT1 inhibitor lingdolinurad for chronic gout and ABP-745 for acute gout and ASCVD — through synchronized US and China Phase 2/3 trials for global commercialization.

Ownership category

akta.pro rank

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical stage company. Expected future revenue from sales of ABP-671 for chronic gout and ABP-745 for acute gout upon regulatory approval.
2. Licensing and Commercialization Rights: Licensing deal with China Medical System Holdings for exclusive commercialization rights to lingdolinurad in China, Hong Kong, and Macao. Company retains global rights outside these territories.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Atom Therapeutics Co is a clinical-stage biopharmaceutical company developing proprietary small molecule drug candidates for inflammatory, metabolic, and cardiovascular diseases. Its lead asset, ABP-671 (lingdolinurad), is a URAT1 inhibitor in global Phase 3 trials for chronic gout and hyperuricemia, while ABP-745 is an anti-inflammatory drug in Phase 2 trials for acute gout and atherosclerotic cardiovascular disease (ASCVD). The company licenses and commercializes its drug candidates through partnerships such as China Medical System Holdings in Greater China.

Product overview

Atom Therapeutics is a clinical-stage biotechnology company developing a portfolio of best-in-class small molecule drugs for inflammatory, metabolic, and cardiovascular diseases. The company's lead product is ABP-671 (lingdolinurad), a URAT1 inhibitor in global Phase 3 trials for chronic gout and hyperuricemia. ABP-745 is a novel anti-inflammatory agent in Phase 2 trials for acute gout and atherosclerotic cardiovascular disease (ASCVD). The pipeline also includes ABP-6118 (xanthine oxidase inhibitor for gout) and ABP-431 (anticancer), both in earlier stages. The company pursues a synchronized development strategy with trials ongoing in both China and the US.

Differentiator

Problem solved

Functional benefit

Products and services

• ABP-671 (Lingdolinurad) A URAT1 inhibitor small molecule drug for chronic gout and hyperuricemia, administered once daily as an oral tablet. Reduces uric acid reabsorption in the kidneys, increases urinary excretion to lower serum uric acid levels, reduces tophi size, and prevents gout attacks. Currently in global Phase 3 trials.
• ABP-745 A novel anti-inflammatory small molecule drug for acute gout and atherosclerotic cardiovascular disease (ASCVD). Demonstrated higher safety and tolerability compared to existing acute gout treatments like colchicine and NSAIDs. In Phase 2 trials for acute gout flares and ASCVD.
• ABP-6118 A xanthine oxidase inhibitor small molecule drug in preclinical development for gout treatment.
• ABP-431

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• China Medical System Holdings Ltd (CMS)coreChannel Partner/ Reseller/ Distributor · 1 December 2024Exclusive commercialization agreement for lingdolinurad (ABP-671) to treat chronic gout and hyperuricemia. CMS obtained exclusive rights to commercialize the drug across mainland China, Hong Kong, and Macao. Atom Therapeutics retains rights for other global markets.
• Gout Education SocietyminorGTM or Marketing PartnerAtom Therapeutics joined Gout Education Society on Gout Awareness Day (May 22) to help educate the public on risk factors and treatment options for gout.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Tigermed: Leading Chinese clinical CRO and emerging biopharma sponsor, comparable as a Hangzhou-headquartered clinical-stage drug developer operating in the same regulatory and capital environment as Atom Therapeutics.
• JW Pharmaceutical: Korean specialty pharma with a URAT1 inhibitor (URICONT/lesinurad) franchise for gout, making it a regionally focused peer competing in Asia with a similar mechanism of action to ABP-671.
• Innovent Biologics: Major Chinese clinical-to-commercial biopharma with a strong gout/urate-lowering pipeline including a URAT1 inhibitor, making it a directly relevant China-based peer targeting the same indication as ABP-671.

Direct peers

• Kissei Pharmaceutical: Japanese specialty pharma that developed and markets dotinurad (URECE), a URAT1 inhibitor for gout and hyperuricemia — the most directly competitive commercialized molecule to ABP-671, addressing the same target and indication.
• Ardea Biosciences (AstraZeneca): Developed lesinurad (Zurampic), a URAT1 inhibitor approved for chronic gout, providing direct mechanistic and clinical comparability to ABP-671, though lesinurad was ultimately withdrawn for renal safety — a key cautionary data point for the class.
• Teijin Pharma: Developed and markets febuxostat (Feburic), a leading branded oral urate-lowering therapy for chronic gout, making it a direct global competitor that ABP-671 must clinically differentiate against in efficacy and safety.

Broad incumbents

• ChemoCentryx (Amgen): Developed oral small-molecule therapies for inflammatory diseases (e.g., TAVNEOS for ANCA-associated vasculitis), making it a broadly comparable late-stage small-molecule inflammation biotech that was ultimately acquired by a large pharma.
• Madrigal Pharmaceuticals: Late-stage clinical biotech that developed resmetirom (Rezdiffra), an oral small-molecule therapy for metabolic liver disease — comparable in being a clinical-to-commercial small-molecule company targeting metabolic and inflammatory conditions.
• Horizon Therapeutics (Amgen): Marketed Krystexxa (pegloticase) for refractory chronic gout, making it a relevant commercial-stage peer in the gout therapeutic area, though addressing a different (refractory) patient segment than ABP-671's first-line positioning.

Emerging players

• Viking Therapeutics: Clinical-stage US biotech developing oral small-molecule therapies for metabolic and inflammatory diseases — comparable in development stage, modality, and therapeutic area focus to Atom Therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/atombioscience
• LinkedInlinkedin.com/company/atom-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atom Therapeutics Co